Researchers announced that Eli Lilly will present new findings on its cancer drug portfolio at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. This includes results from a Phase 3 study of Retevmo (selpercatinib) as a treatment for non-small cell lung cancer (NSCLC) that showed significant improvements in patient outcomes. Additionally, data on Verzenio (abemaciclib) for advanced liposarcoma and other investigational therapies will also be highlighted.

This research is important for anyone interested in cancer treatments, especially those with specific types of lung or soft tissue cancers. The findings from the Retevmo study indicate a meaningful increase in event-free survival for patients with RET fusion-positive NSCLC, which could lead to better long-term outcomes. For individuals diagnosed with these cancers, advancements like these could offer new hope and options for treatment.

The evidence presented at ASCO will include both early-stage and more advanced studies, such as the Phase 3 LIBRETTO-432 trial for Retevmo and the investigator-initiated SARC041 study for Verzenio. While these results are promising, it’s important to note that they are still in the clinical trial phase and not yet widely available for general use. This means that while the data is encouraging, further research is needed to confirm these benefits for broader patient populations.

If you’re looking to stay informed about the latest in cancer treatments, consider following updates from major oncology conferences like ASCO. This can help you learn about new therapies and advancements that may become available in the future.

Source: investor.lilly.com